Simultaneous discoveries in art and science highlight humanity's shared creativity, problem-solving, and the ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Crispant analysis in zebrafish serves as a powerful tool for the rapid functional screening of genes implicated in bone fragility disorders, like osteogenesis imperfecta and osteoporosis.

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...